Cognis will unveil its new range of high quality omega-3 fish oil products at this year?s Health Ingredients Europe event in Frankfurt. Under the brand name Omevital?, and available in ethyl ester and triglyceride forms, the new range of marine-origin oils delivers products of outstanding quality and purity, ultra-refined through state-of-the-art manufacturing processes, in accordance with Pharma GMP standards.
The King’s Centre for Military Health Research (KCMHR) has received further funding from the UK Ministry of Defence to continue its research into the health and well-being of military personnel, many of whom have served in Iraq. The research, which began in 2003 as a prospective investigation of the physical and psychological health of over 12,000 UK service personnel serving in Iraq, will be monitoring service personnel more widely, including those deployed to Afghanistan.
The first human Alzheimer’s vaccine trial in the UK is being resurrected in a study launched by the Alzheimer?s Research Trust. The charity hopes it will indicate whether immunisation against Alzheimer’s is an effective method of tackling the disease.
Proteins found in the blood can indicate an increased risk of Alzheimer’s disease, according to groundbreaking new research published today (30 October) in the journal Brain. It is the first time markers for the development of Alzheimer’s have been identified in blood. The findings take researchers a step closer to knowing whether a blood test can be used to diagnose and measure progression of the Alzheimer’s disease.
As we all know, life is very stressful these days, specially in corporate sector. People work more, skip meals and miss sleep. Everyone is trying to achieve the targets, and then result is stress. In stress, mind grows all the negative thoughts like fear, anger, guilt, anxiety, frustration, and so on. And in response to all these, body produces catecholamines which results in increased acidity, faster beating of hearts, tensing of muscles, shooting of blood pressure and restless mind. Finally, all these end up with hypertension, thyroid problems, diabetes mellitus, and many other chronic diseases.
Diabetes is a growing health problem. Giving antioxidants is recognised as one way of helping people with diabetes to control their blood sugar levels. The herbal medicine extracted from seeds of the Milk Thistle, Silybum marianum (silymarin) is known to have antioxidant properties and research published this week in Phytotherapy Research shows that this extract can help people significantly lower the amount of sugar bound to haemoglobin in blood, as well as reducing fasting blood sugar levels.
A report released by the Health Protection Agency shows that around one in 50 Injecting Drug Users (IDUs) in the UK are now infected with HIV. This is around twice the level seen at the beginning of the decade. In particular the HIV prevalence amongst those injecting for less than three years has increased since 2002. Increasing evidence suggests that crack cocaine is a major factor.
Soot particles spewing from the exhaust of diesel trucks constitute a major contributor to the alarmingly high rates of asthma symptoms among school-aged children in the South Bronx, according to the results of a five-year study by researchers at New York University?s School of Medicine and Robert F. Wagner Graduate School of Public Service.
A consortium of American and Canadian researchers report in Science Express, a rapid online publication by the journal Science, the discovery of a new genetic link to Crohn’s disease. While most of the mutations in the gene, which codes for a receptor in a major inflammatory pathway, are strongly associated with Crohn?s, surprisingly, one type of mutation appears to confer significant protection. The finding, say the researchers, points to a crucial target for drugs that might better manage Crohn?s disease and ulcerative colitis.
Schering-Plough reported data from EPIC3, a large ongoing clinical study, showing that retreatment with PEG-INTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy can result in sustained virologic response(1) (SVR) in patients with chronic hepatitis C who failed previous treatment with any alpha interferon-based combination therapy, including peginterferon regimens. In this study, 56 percent of patients who had undetectable virus (HCV-RNA) after 12 weeks went on to achieve SVR with a 48-week course of therapy. Of the first 1,354 patients retreated, approximately 38 percent had undetectable virus at week 12. Importantly, patients who did not have undetectable virus at 12 weeks had little chance of achieving SVR. Overall, 23 percent of patients achieved SVR.